About Sickkids
About SickKids
print        

Michael Moran , PhD

Research Institute
Senior Scientist
Molecular Structure & Function

Director
SPARC BioCentre

University of Toronto
Professor
Department of Molecular Genetics

Professor
Banting and Best Department of Medical Research

Chair Positions
Canada Research Chair
Molecular Signatures

Other Positions

Affiliate Scientist
Princess Margaret Hospital, Ontario Cancer Institute
University Health Network


Phone: 647-235-6435
Fax: 416-813-5993
e-mail: m.moran@utoronto.ca
Alternate Contact: Shirley Thompson
Alternate Phone: 416-813-7654 x3043
Alternate e-mail: thompson@sickkids.ca

Brief Biography

Dr. Moran completed his PhD in Biochemistry at the National Cancer Institute of Canada’s Cancer Research Laboratory at the University of Western Ontario in 1987. He was an NCIC Fellow at Mount Sinai Hospital (1986-1990), and then joined the University of Toronto in 1990 in the Banting and Best Department of Medical Research, and the Department of Molecular and Medical Genetics. He was an NCIC Scientist from 1991-97 and an MRC/Canadian Institutes for Health Research Scientist from 1997-2002.

Dr. Moran has served on various granting agency study sections related to cancer, and consulted and collaborated with pharmaceutical and biotechnology companies in the area of drug discovery. He helped found the companies Ocata Proteomics and MDS Proteomics, and served as Chief Scientific Officer.

Dr. Moran’s research focus, publications, and invited seminars have addressed the intracellular signaling networks that control growth, survival, and spreading of tumours, and how drugs may be designed to target key components in these molecular networks. His group uses proteomics technologies including mass spectrometry and bioinformatics to identify and characterize proteins activated in cancers, and to determine drug mechanisms of action.

External Funding

  • Canadian Cancer Society Research Institute
  • Canadian Institutes of Health Research
  • Canadian Foundation for Innovation
  • Ontario Institute for Cancer Research
  • Ontario Research Fund
  • National Institutes of Health/National Cancer Institute

Publications

Ernst A, Avvakumov G, Tong  J, Fan Y, Zhao Y, Alberts P, Persaud A, Walker JR, Neculai AM, Neculai D, Vorobyov A, Garg P, Beatty L, Chan PK, Juang YC, Landry MC, Yeh C, Zeqiraj E, Karamboulas K, Allali-Hassani A, Vedadi M, Tyers M, Moffat J, Sicheri F, Pelletier L, Durocher D, Raught B, Rotin D, Yang J, Moran MF, Dhe-Paganon S, and Sidhu SS (2013) A strategy for modulation of enzymes in the ubiquitin system. Science 339, 590-595.

Vojvodic M, Hansford LM, Morozova O, Blakely KM, Taylor P, Fathers KE, Moffat J, Marra M, Smith KM, MF Moran, and DR Kaplan (2013) A phosphoproteomics approach to identify kinase inhibitor target in lymphoma-like primary cell lines. Current Drug Discovery Technologies 10(4): 283-304.

Kreiger JR, Taylor P, Gajadhar AS, Guha A, Moran MF, and McGlade CJ (2013) Identification and SRM quantification of endocytosis factors associated with numb. In revision, Molecular and Cellular Proteomics 12(2): 499-514.  

Jin L, Y Sydorskyy, P Taylor, MF Moran, and JR St-Germain (2012) Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry, SRM-MS. Current Protocols in Chemical Biology 4:65-81.   

Li L, Tibiche C, Fu C, Kaneko T, Moran MF, Schiller MR, SSC Li, and E Wang (2012) The human phosphotyrosine signaling network: origin, evolution, and hotspots of hijacking in cancer. Genome Research 22(7): 1222-30.

Hembrough T, S Thyparambil, WL Liao, M Darfler, J Abdo, K Bengali, P Taylor, J Tong, H Lara-Guerra, TK Waddell, MF Moran, MS Tsao, D Krizman, and J Burrows (2012) Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue. Clinical Proteomics 9(1):5-15.    

Yu C, A Shabab, J St-Germain, Y Liu, X Yu, MF Moran, MD Cooper, and GRA Ehrhardt (2012) Purification and identification of cell surface antigens using monoclonal CLRB antibodies. J. Immunol Methods 386:43-49.

Bocchinfuso, D.G., Taylor, P., Ross, E., Ignatchenko, A., Ignatchenko, V., Kislinger, T., Pearson, B.J., and Moran, M.F. (2012). Proteomic profiling of the planarian schmidtea mediterranea and its mucous reveals similarities with human secretions and those predicted for parasitic flatworms. Mol Cell Proteomics 11, 681-691.

Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain JR, Jin, LL, Harris IS, Mori J, Mak TW, Senis YA, Ostman A, Moran MF, and BG Neel (2011) Global proteomic assessment of the classical protein-tyrosine phosphatome and “redoxome”.  Cell 146:826-40.    

Organ SL, Tong J, Taylor P, St-Germain JR, Navab R, MF Moran, and MS Tsao (2011) Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-Met signaling.  J Proteome Res. 10(7):3200-11.

Mao X, B Cao, T Wood, R Hurren, J Tong, X Wang, P Spagnuolo, N MacLean, MF Moran, A Datti, J Wrana, RA Batey, and AD Schimmer (2011) A small molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.  Blood 117(6):1986-97.

Wei Y, Tong J, Taylor P, Strumpf D, Ignatchenko V, Pham NA, Yanagawa N, Liu G, Jurisica I, Shepherd FA, Tsao MS, Kislinger T, MF Moran (2011) Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. J Proteome Res  10(1):161-74

Jin LL, Tong J, Prakash A, Peterman SM, St-Germain J, Taylor P, Trudel S, Moran MF (2010) Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry.  J Proteome Res  9(5):2752-61

Morozova O, Vojvodic M, Grinshtein N, Hansford LM, Blakely KM, Maslova A, Hirst M, Cezard T, Morin R, Moore R, Smith KM, Miller F, Taylor P, Thiessen N, Varhol R, Zhao Y, Jones S, Moffat J, Kislinger T, Moran MF, Kaplan DR, Marra MA (2010) Systems-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.  Clinical Cancer Research   16(18):4572-82

St-Germain JR, Taylor P, Tong J, Jin LL, Nikolic A, Stewart II, Ewing RM, Dharsee M, Li Z, Trudel S, Moran MF. (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A, 106(47):20127-32

Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A. (2009) Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 69(19):7548-56

Tong J, Taylor P, Peterman SM, Prakash A, Moran MF. (2009) EGF receptor phosphorylation sites S991 and Y998 are implicated in the regulation of receptor endocytosis, protein-protein interactions, and p38 MAPK-dependent phosphorylation at S1039 and T1041. Mol. Cell. Proteomics, doi: 10.1074

Taylor P, Neilsen PA, Trelle MB, Horning OB, Andersen MB, Vorm O, Moran MF, Kislinger T. (2009) Automated 2D peptide separation on a 1D Nano-LC-MS system. J Prot Res 8(3):1610-1616